Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Mereo BioPharma Group plc (MREO)

1.18   -0.02 (-1.67%) 08-18 06:14
Open: 1.16 Pre. Close: 1.2
High: 1.21 Low: 1.16
Volume: 503,687 Market Cap: 138(M)
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.21 - 1.22 1.22 - 1.23
Low: 1.14 - 1.15 1.15 - 1.16
Close: 1.17 - 1.18 1.18 - 1.19

Technical analysis

as of: 2022-08-17 4:25:12 PM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.81     One year: 2.13
Support: Support1: 1.11    Support2: 0.92
Resistance: Resistance1: 1.55    Resistance2: 1.83
Pivot: 1.21
Moving Average: MA(5): 1.23     MA(20): 1.27
MA(100): 0.98     MA(250): 1.48
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 33.2     %D(3): 38.7
RSI: RSI(14): 44.7
52-week: High: 2.93  Low: 0.3
Average Vol(K): 3-Month: 7,703 (K)  10-Days: 1,361 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ MREO ] has closed above bottom band by 36.0%. Bollinger Bands are 57.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 16 Aug 2022
European ADRs Nudge Lower in Tuesday Trading - InvestorsObserver

Tue, 16 Aug 2022
Cobra Resources provides Wudinna Project update - Global Mining Review

Fri, 12 Aug 2022
Is Mereo BioPharma Group plc - ADR (MREO) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Fri, 12 Aug 2022
Mereo BioPharma Group (NASDAQ:MREO) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat

Wed, 03 Aug 2022
American Rare Earths" assays up to 5,065 ppm total rare earth oxide provide upside potential at Halleck Creek - Proactive Investors USA

Fri, 17 Jun 2022
Mereo BioPharma: Activist Pressure In A Net-Net Biopharma - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 109 (M)
Shares Float 50 (M)
% Held by Insiders 0 (%)
% Held by Institutions 79.7 (%)
Shares Short 5,210 (K)
Shares Short P.Month 3,560 (K)

Stock Financials

EPS -0.36
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.81
Profit Margin (%) 34.9
Operating Margin (%) -57.5
Return on Assets (ttm) -13.9
Return on Equity (ttm) 34.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.17
Sales Per Share 0.33
EBITDA (p.s.) -0.2
Qtrly Earnings Growth 0
Operating Cash Flow -5 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -3.32
PEG Ratio 0
Price to Book value 1.43
Price to Sales 3.52
Price to Cash Flow -24.53

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.